Saturday, 29 June 2013

UK government supports three-person IVF

The UK is expected to become the first country to allow the creation of babies using the DNA of three different people, after the government backed the new IVF technique. Draft regulations will be produced later this year and the procedure could be offered within two years. Experts say three-person IVF could eliminate debilitating and potentially fatal mitochondrial diseases that are passed on from mother to child, however opponents say it is unethical and could set the UK on a "slippery slope".

Mitochondria are the tiny organelles inside cells that produce energy for the body in the form of adenosine triphosphate (ATP); everyone inherits them from their mother as they are present in the egg cell which is fertilised by the sperm. Defective mitochondria affect one in every 6,500 babies, which can leave them starved of energy and results in muscle weakness, blindness, heart failure and death in the most extreme cases.

Thanks to the two new techniques that have been devised by scientists, it is now possible to take an empty donor egg with non-faulty mitochondrial DNA and then fertilise it with a gamete nucleus from each parent. This would allow a couple to have a child that is genetically related to them both, but does not carry the defective mitochondrial DNA. Because the mitochondria contain a small amount of DNA it also means that the child is created using the DNA from three people.

Earlier this year, a public consultation by the Human Fertilisation and Embryology Authority (HFEA) concluded that there was "general support" for the idea and that there was no evidence that the advanced form of IVF was unsafe. The chief medical officer for England, Prof Dame Sally Davies, said: "Scientists have developed ground-breaking new procedures which could stop these diseases being passed on, bringing hope to many families seeking to prevent their future children inheriting them." She said there were "clearly some sensitive issues here" but said she was "personally very comfortable" with altering mitochondria.

Jack

Saturday, 22 June 2013

Fall in excess diabetes deaths

Research suggests that the extra risk of dying for people with diabetes has fallen sharply since the mid 1990s. In 2009 people with diabetes were 1.5 times more likely than people without diabetes to die within a given time period - down from being two times as likely in 1996. The study that looked into this, in journal Diabetologia covering millions of Canadian and UK patients, concludes this may have resulted from better treatment and earlier diagnosis.

Since the mid 1990s the number of people diagnosed with diabetes in the UK has climbed from less than one and a half million to three million. The disease and its often fatal complications, which include heart disease, stroke and kidney failure, pose a huge and growing challenge for the NHS. However this study points to progress in cutting deaths.

The findings are based on population-based databases from Ontario and the UK over the years 1996 to 2009. The researchers compared mortality rates in people with diabetes, including types 1 and 2, and those without. In the UK cohort, covering more than three million patients, the excess risk of death for people with diabetes in 1996 was 114%; by 2009 this had fallen to 65%. In the Ontario database, comprising about 10 million patients, it fell from 90% to 51%. This narrowing of the mortality gap was seen across all age-groups and in both men and women. However, the authors acknowledge their findings should be treated with caution.

They speculate that the improvements may be due to more aggressive treatment, including control of blood pressure and blood glucose levels. But they say the findings may also reflect improved screening, meaning more patients nowadays have not had diabetes for so long. Dr Alasdair Rankin, director of research for diabetes UK, said the research was "really good news", but he warned there was still a long way to go. He said: "Every year many thousands of people with diabetes in the UK are still dying before their time. This is unacceptable and urgent action is needed to further improve the situation." There are also wide regional variations across the country in helping patients manage their condition so this should now become a key focus. By supporting patients to better manage their diabetes, progress can be made to reduce the number of patients who suffer complications including amputations or loss of sight.

Jack

Saturday, 15 June 2013

Patch offers alternative method for injections

A skin patch that can deliver vaccines cheaply and effectively has been shown off by its inventor, Prof Mark Kendall, at the TEDGlobal conference in Edinburgh. He said that using a patch rather than a needle could transform disease prevention around the world, and offered hope of usable vaccines for diseases such as malaria.

The nanopatch overcomes some of the drawbacks of syringe-given vaccines such as needle phobia and the possibility of contamination caused by dirty needles. Thousands of tiny projections in the patch release the vaccine which is applied into the skin in dry form. He explained: "The projections on the nanopatch work with the skin's immune system. We target these cells that reside just a hair's breadth from the surface of the skin." He went on to say: "It seems that we may have been missing the immune sweet spot which may be in the skin rather than the muscle which is where traditional needles go."

In tests at his laboratory in Queensland University, Brisbane, the nanopatch was used to administer the flu vaccine. Researchers noticed that the immune responses for vaccines administered with the nanopatch were completely different to those given by a traditional syringe. The amount of vaccine needed for it to be effective is also much lower, up to one hundredth of the traditional dose. As well as this, another shortcoming of traditional vaccines is that, because they are liquid, they need to be kept refrigerated between the lab and clinic. However this is not the case with the nanopatch which can be stored at 23°C for up to a year. This is significant because half of vaccines in Africa are not working because refrigeration has failed at some point in the chain.

The news of the nanopatch was given a huge welcome by the British Society for Immunology, Dr Diana Williamson commented: "This approach holds out hope for easy and large-scale vaccination, as it targets a type of immune cell, called the Langerhans cell, that is abundant in the skin. These cells avidly take up the vaccine and are able to kick-start the immune response." However she also warned that one of the potential issues with skin delivery is transit time and ensuring adequate delivery of the vaccine payload. In addition to this there may be issues of tolerability of the patch in some people. However, if these issues can be overcome, the approach does hold out the potential to dispense with conventional needle-based 'intra-muscular' delivery. The nanopatch will soon begin field tests in Papua New Guinea where vaccines are in short supply.

Jack

Saturday, 8 June 2013

MS 'immune training' trial

An experimental treatment to stop the body attacking its own nervous system in patients with multiple sclerosis appears safe in trials. The myelin sheath which coats the axons of nerves is destroyed in multiple sclerosis, by the immune system thinking that myelin is a foreign body. This leaves the nerves struggling to pass on messages. The study, which involved nine patients and was reported in Science Translational Medicine, tried to train the immune system to cease its assault on myelin.

The researchers, from Northwestern University Feinberg School of Medicine, took blood samples and coupled white blood cells to fragments of myelin. This was then injected back into patients to make them tolerate myelin. They reported that the therapy appeared safe, and despite the sample size being too small to prove whether it benefited patients, they did observe a calming of the immune reaction.

Prof Stephen Miller said: "Our approach leaves the function of the normal immune system intact. That's the holy grail." He continued to say: "We want to treat patients as early as possible in the disease before they have paralysis due to myelin damage, once the myelin is destroyed, it's hard to repair that."

Dr Susan Kohlhaas, head of biomedical research at the MS society, also commented: "Being able to specifically stop the immune system attacking myelin but still keeping it fully functional poses an exciting potential therapy for people with MS." She was intrigued by the success that had been shown in this small study, but said that more research is needed and she would eagerly await the results of any future larger clinical trials of this therapy.

Jack